Skip to main content

GT All-Stars, Next-Gen Sequencing, DiaDexus, NIH Roadmap, and Bioimaging

Premium

 

In 2003, Genome Technology celebrated its third annual All-Stars, our awards to scientists who were chosen by a panel of experts as the most deserving of recognition. That year, winners included George Church, Pat Brown, Lincoln Stein, Ruedi Aebersold, David Cox, Rolf Apweiler, Jeffrey Trent, and Francis Collins. Five years made quite a difference for many of them. Church has since launched his Personal Genomes Project and handed off his latest brainchild, a next-gen sequencing tool called the Polonator, for commercialization to manufacturing giant Danaher Motion. Stein accepted a position at the Ontario Institute for Cancer Research, headed up by Tom Hudson, and now spends most of his time there while continuing to maintain a presence at his longtime home of Cold Spring Harbor Laboratory. And Collins stepped down as director of NHGRI at the end of August.

Also in GT's November 2003 issue, we reported that NHGRI was launching a new grant program to fund development of technology to drastically reduce the cost of DNA sequencing. In the time since, the genome institute's awards have helped a number of researchers and companies develop next-gen sequencing tools. NHGRI recently made the last of its $100,000 genome awards, reasoning that by next year that goal will have been met. Indeed, some companies — including Applied Biosystems and Illumina — say that they've already sequenced a human genome for less than $100,000, and startup Complete Genomics has said that by next year it will be able to sequence a human genome for $5,000.

Five years ago, we also profiled DiaDexus, a genomics-based diagnostic company founded by Randy Scott and George Poste in 1997. Earlier this year, DiaDexus announced that it had received FDA clearance for an automated version of its test for stroke and heart disease susceptibility. Meantime, Scott is CEO of Genomic Health, which in 2004 launched OncotypeDX, a genomic test to predict chances for both recurrence and chemotherapy efficacy in breast cancer patients. Poste is director of the Biodesign Institute at Arizona State University, where he is also a professor of biology.

A year ago in GT, we reported that the Clinical Translational Science Awards consortium, founded by NIH in 2006, had been given a boost of $574 million over five years. The consortium is part of Elias Zerhouni's Roadmap Initiative, a program that has issued large amounts of funding for clinical and translational research. In this issue, we profile Oregon Clinical and Translational Research Institute, one of the first institutes to win a grant through the CTSA program.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.